• Orthocell jumps 35% after signing global license deal
  • Imricor in with Siemens deal on 3D imaging system
  • CardieX submits “Pulse” application with US FDA 

Orthocell (ASX:OCC) jumped by over 35% this morning after signing a 25-year exclusive patent and trademark license deal with BioHorizons for the manufacture of Striate+.

Striate+ is a resorbable collagen membrane used in guided bone and tissue regeneration procedures.

Under the deal, US-based BioHorizons has agreed to pay Orthocell $23.1 million in return for the granting of an exclusive licence of intellectual property (IP) for Striate+.

The licence relates to the Striate+ products for dental and oral-maxillofacial procedures.’

Specifically, Orthocell will grant BioHorizons an exclusive licence of two patent families covering a collagen scaffold for cell growth, and a method for producing a collagen membrane.

This will incorporate all associated patent applications, improvements and know-how, as well as the Striate+ trademark.

“The agreements with BioHorizons represent a significant milestone for Orthocell,” said Orthocell CEO, Paul Anderson.

“It will also provide further external commercial and technical validation of the CelGro collagen scaffold platform, from which the Striate+ dental products were developed,” he added.

Orthocell’s CellGro technology

Orthocell’s Remplir (formerly CelGro) scaffold is a unique collagen scaffold that’s bio-compatible, bio-absorbable and mechanically strong.

This allows for multiple uses either on its own, or in combination with autologous cells or growth factors.

Orthocell has had some recent success with nerve reconstruction, reporting earlier this month that the final data read-out of all patients in its nerve reconstruction trial has shown encouraging results.

The regenerative medicine company said results demonstrated early recovery of muscle function in paralysed upper limbs, with continued improvement seen at the 12-month and 24-month checkpoints.

Imricor signs new deals with Siemens

Meanwhile, Imricor Medical Systems (ASX:IMR) jumped 26% after announcing two new agreements with Siemens Healthcare that will see Imricor deploy its new 3D mapping system on the Siemens MRI platform.

Imricor’s 3D mapping system will allow Siemens iCMR (Cardiac Magnetic Resonance Imaging) sites to participate in a planned VT (ventricular tachycardia) clinical trial.

Prototype versions of the Imricor 3D mapping system will be evaluated at certain Siemens’ sites in Q3.

“The entire 3D mapping system program is a result of the close partnership we have with Siemens, and we are very pleased with how our partnership continues to grow and mature.”

CardieX asks for FDA approval

In other health news, CardieX (ASX:CDX) jumped 8% in morning trading after announcing it has submitted an application to the US FDA for the clearance of its “Pulse” dual blood pressure monitor.

Pulse is a digital and device ecosystem for both consumers and clinicians built upon CardieX’s existing FDA-cleared SphygmoCor central blood pressure technology.

Developed by subsidiary ATCOR, CardieX claims that SphygmoCor is considered to be the “gold standard” of central blood pressure measurement.

Pulse’s health parameters have been fully patented and trademarked, and an FDA clearance will allow the device to be marketed under the company’s CONNEQT brand.

CardieX says the Pulse device will target global markets in home health monitoring, remote patient management, and decentralised clinical trials.